{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infusion+of+NK+cells&page=5",
    "query": {
      "intervention": "Infusion of NK cells",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 175,
    "total_pages": 18,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infusion+of+NK+cells&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infusion+of+NK+cells&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T10:21:57.319Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05588453",
      "title": "Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Metastatic Malignant Neoplasm in the Brain",
        "Metastatic Melanoma",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Natural Killer Cell Therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kari Kendra",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2023-03-01",
      "completion_date": "2027-04-15",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-10-05T10:21:57.319Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05588453"
    },
    {
      "nct_id": "NCT06508489",
      "title": "A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "SAR443579",
          "type": "BIOLOGICAL"
        },
        {
          "name": "venetoclax",
          "type": "DRUG"
        },
        {
          "name": "azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2024-08-13",
      "completion_date": "2025-08-08",
      "has_results": false,
      "last_update_posted_date": "2025-08-22",
      "last_synced_at": "2026-10-05T10:21:57.319Z",
      "location_count": 5,
      "location_summary": "Duarte, California • The Bronx, New York • Columbus, Ohio + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06508489"
    },
    {
      "nct_id": "NCT01948180",
      "title": "Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, Extranodal NK-T-Cell",
        "EBV"
      ],
      "interventions": [
        {
          "name": "baltaleucel-T",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cell Medica Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2014-09",
      "completion_date": "2018-09-07",
      "has_results": false,
      "last_update_posted_date": "2019-03-13",
      "last_synced_at": "2026-10-05T10:21:57.319Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • Rochester, Minnesota • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01948180"
    },
    {
      "nct_id": "NCT02099539",
      "title": "QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed or Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "N-803",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Altor BioScience",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2014-10-06",
      "completion_date": "2018-06-19",
      "has_results": true,
      "last_update_posted_date": "2024-09-26",
      "last_synced_at": "2026-10-05T10:21:57.319Z",
      "location_count": 4,
      "location_summary": "Minneapolis, Minnesota • St Louis, Missouri • Buffalo, New York + 1 more",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02099539"
    },
    {
      "nct_id": "NCT02452697",
      "title": "Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myeloid Malignancies",
        "Lymphoid Malignancies"
      ],
      "interventions": [
        {
          "name": "NK Cell enriched-DLI only",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NK-DLI + DUK-CPG-001",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cristina Gasparetto",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2016-06-08",
      "completion_date": "2024-10",
      "has_results": true,
      "last_update_posted_date": "2024-02-20",
      "last_synced_at": "2026-10-05T10:21:57.319Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02452697"
    },
    {
      "nct_id": "NCT00660166",
      "title": "Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Myeloma",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "NK-Cell Infusion",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Tufts Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "13 Years to 70 Years"
      },
      "enrollment_count": 13,
      "start_date": "2006-04",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2012-06-27",
      "last_synced_at": "2026-10-05T10:21:57.319Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00660166"
    },
    {
      "nct_id": "NCT00089453",
      "title": "Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Bortezomide",
          "type": "DRUG"
        },
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Interleukin",
          "type": "DRUG"
        },
        {
          "name": "Infusion #1",
          "type": "PROCEDURE"
        },
        {
          "name": "Leukapheresis #2",
          "type": "PROCEDURE"
        },
        {
          "name": "Infusion #2",
          "type": "PROCEDURE"
        },
        {
          "name": "Auto Graft",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2003-09",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2012-04-19",
      "last_synced_at": "2026-10-05T10:21:57.319Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00089453"
    },
    {
      "nct_id": "NCT06152809",
      "title": "CIML NK Cells With Venetoclax for AML",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Myeloid Leukemia Recurrent",
        "Leukemia",
        "Leukemia, Myeloid"
      ],
      "interventions": [
        {
          "name": "Cytokine-Induced Memory-like Natural Killer Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Interleukin-2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2024-02-20",
      "completion_date": "2027-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-10-05T10:21:57.319Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06152809"
    },
    {
      "nct_id": "NCT05700630",
      "title": "Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV-1-infection",
        "ART",
        "Cd4+ Lymphocyte Deficiency",
        "Lymphoid Tissue; Infection",
        "Interleukin"
      ],
      "interventions": [
        {
          "name": "FT538",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2024-07-15",
      "completion_date": "2024-08-21",
      "has_results": false,
      "last_update_posted_date": "2024-02-26",
      "last_synced_at": "2026-10-05T10:21:57.319Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05700630"
    },
    {
      "nct_id": "NCT06377228",
      "title": "A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory Lupus Nephritis",
        "Refractory Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "TAK-007",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Chemotherapy Agents",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2025-06-13",
      "completion_date": "2030-09-02",
      "has_results": false,
      "last_update_posted_date": "2025-04-06",
      "last_synced_at": "2026-10-05T10:21:57.319Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06377228"
    }
  ]
}